Homocysteine and serum markers of immune activation in primary dystonia.
The cause of primary dystonia remains unknown. Several reports point to immune system disturbances in primary dystonia and a recent study demonstrated hyperhomocysteinemia in cervical dystonia. Homocysteine (HCY) is an amino acid and elevated HCY concentrations were shown to be associated with immune system activation and increased neopterin serum concentrations. We examined HCY serum concentrations together with serum markers of immune activation in patients with different types of primary dystonia. Eighty-three patients with different types of primary dystonia were included and investigated at least 3 months following botulinum toxin treatment. Thirty-six healthy volunteers with similar age and sex distribution served as controls. Total serum HCY, kynurenine, and tryptophan concentrations were determined by high-performance liquid chromatography; neopterin, folate, and vitamin B12 concentrations were measured by immunoassays. Routine blood analysis, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood count (WBC), was performed. Patients with primary dystonia had significantly higher HCY concentrations compared to controls. Among the dystonia subtypes, no significant difference of HCY serum concentrations was observed. CRP and ESR were within the normal range in >90% of the patients and all had normal WBC. Neopterin, kynurenine, and tryptophan serum concentrations were similar in patients and controls and not correlated with HCY serum concentrations. The results provide evidence against enhanced cellular immune activation in patients with primary dystonia. However, hyperhomocysteinemia was present in all dystonia subtypes and unrelated to immune activation in this study. HCY is a neuronal excitotoxic amino acid and hyperhomocysteinemia is considered an independent vascular risk factor. Further studies are required to define the background of hyperhomocysteinemia in primary dystonia.
Muller
Ulf J
UJ
University Hospital of Neurology, Medical University Innsbruck, Innsbruck, Austria. joerg.mueller@uibk.ac.at
Frick
Barbara
B
Winkler
Christiana
C
Fuchs
Dietmar
D
Wenning
Gregor K
GK
Poewe
Werner
W
Mueller
Joerg
J
D000328:Adult; D000368:Aged; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001905:Botulinum Toxins / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D020821:Dystonic Disorders / Q000097:blood* / Q000145:classification / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D005492:Folic Acid / Q000097:blood; D005500:Follow-Up Studies; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D007109:Immunity / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D014805:Vitamin B 12 / Q000097:blood
D018726:Anti-Dyskinesia Agents; D015415:Biomarkers; D006710:Homocysteine; D002097:C-Reactive Protein; D005492:Folic Acid; D001905:Botulinum Toxins; D014805:Vitamin B 12